Arcturus Therapeutics (ARCT) Short Interest Ratio & Short Volume $15.66 -0.07 (-0.45%) (As of 09:33 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Arcturus Therapeutics Short Interest DataArcturus Therapeutics (ARCT) has a short interest of 4.37 million shares, representing 17.78% of the float (the number of shares available for trading by the public). This marks a -2.46% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.1, indicating that it would take 11.1 days of the average trading volume of 463,826 shares to cover all short positions.Current Short Interest4,370,000 sharesPrevious Short Interest4,480,000 sharesChange Vs. Previous Month-2.46%Dollar Volume Sold Short$80.15 millionShort Interest Ratio11.1 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares27,087,000 sharesFloat Size24,580,000 sharesShort Percent of Float17.78%Today's Trading Volume10,134 sharesAverage Trading Volume463,826 sharesToday's Volume Vs. Average2% Short Selling Arcturus Therapeutics? Sign up to receive the latest short interest report for Arcturus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartARCT Short Interest Over TimeARCT Days to Cover Over TimeARCT Percentage of Float Shorted Over Time Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. Arcturus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20244,370,000 shares $80.15 million -2.5%17.8%11.1 $18.34 11/15/20244,480,000 shares $71.77 million -2.2%18.2%11.4 $16.02 10/31/20244,580,000 shares $81.20 million +3.4%18.5%12.8 $17.73 10/15/20244,430,000 shares $92.90 million -3.7%17.9%12 $20.97 9/30/20244,600,000 shares $106.77 million -12.1%18.6%11.8 $23.21 9/15/20245,230,000 shares $108.52 million -2.8%21.2%11.6 $20.75 Get the Latest News and Ratings for ARCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20245,380,000 shares $113.52 million -1.5%21.8%10.5 $21.10 8/15/20245,460,000 shares $110.62 million +1.9%22.1%9.5 $20.26 7/31/20245,360,000 shares $125.75 million +2.9%21.7%9.1 $23.46 7/15/20245,210,000 shares $121.81 million +11.3%21.2%8.7 $23.38 6/30/20244,680,000 shares $113.96 million +6.9%19.0%7.6 $24.35 6/15/20244,380,000 shares $135.78 million +6.6%17.8%7.4 $31.00 5/31/20244,110,000 shares $159.51 million -0.5%16.7%7.4 $38.81 5/15/20244,130,000 shares $119.83 million -16.1%16.8%8.2 $29.02 4/30/20244,920,000 shares $125.80 million +6.7%20.0%9.7 $25.57 4/15/20244,610,000 shares $135.12 million -4.2%18.8%9.7 $29.31 3/31/20244,810,000 shares $162.43 million +14.3%19.6%10.6 $33.77 3/15/20244,210,000 shares $152.87 million -0.2%17.2%10 $36.31 2/29/20244,220,000 shares $163.57 million -6.6%17.3%10.1 $38.76 2/15/20244,520,000 shares $172.62 million +3.4%18.6%11.4 $38.19 1/31/20244,370,000 shares $144.08 million +5.3%18.0%10.3 $32.97 1/15/20244,150,000 shares $137.57 million +0.5%17.1%9.8 $33.15 12/31/20234,130,000 shares $130.22 million -6.8%17.0%10.1 $31.53 12/15/20234,430,000 shares $127.94 million -18.4%18.2%10.9 $28.88 11/30/20235,430,000 shares $129.99 million +7.1%22.3%13.5 $23.94 11/15/20235,070,000 shares $114.18 million +1.6%20.8%13.1 $22.52 10/31/20234,990,000 shares $95.31 million +4.2%20.6%13.6 $19.10 10/15/20234,790,000 shares $109.79 million +3.9%19.8%12.3 $22.92 9/30/20234,610,000 shares $117.79 million +10.0%19.0%10.8 $25.55 9/15/20234,190,000 shares $119.58 million +6.6%17.3%9.4 $28.54 8/31/20233,930,000 shares $119.28 million +0.3%16.2%8.8 $30.35 8/15/20233,920,000 shares $117.36 million +2.1%16.2%8.9 $29.94 7/31/20233,840,000 shares $134.25 million +5.8%15.9%8.6 $34.96 7/15/20233,630,000 shares $128.65 million +9.0%15.0%8.4 $35.44 6/30/20233,330,000 shares $95.50 million -8.0%13.8%7.7 $28.68 6/15/20233,620,000 shares $99.48 million +0.3%15.0%6.8 $27.48 5/31/20233,610,000 shares $98.70 million +8.7%15.0%7 $27.34 5/15/20233,320,000 shares $101.69 million +5.7%13.8%6.4 $30.63 4/30/20233,140,000 shares $83.59 million +11.7%13.7%6.4 $26.62 4/15/20232,810,000 shares $77.47 million +6.0%12.3%5.9 $27.57Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. 3/31/20232,650,000 shares $63.52 million +4.3%11.6%5.8 $23.97 3/15/20232,540,000 shares $40.49 million +8.6%11.1%7.5 $15.94 2/28/20232,340,000 shares $38.03 million +4.9%10.2%5.8 $16.25 2/15/20232,230,000 shares $41.32 million +21.9%9.8%5.5 $18.53 1/31/20231,830,000 shares $38.67 million +9.6%8.0%3.8 $21.13 1/15/20231,670,000 shares $33.20 million -12.1%7.3%2.9 $19.88 12/30/20221,900,000 shares $32.22 million -27.8%8.3%3.3 $16.96 12/15/20222,630,000 shares $47.97 million -7.4%11.5%4.5 $18.24 11/30/20222,840,000 shares $52.37 million +9.2%12.4%5.2 $18.44 11/15/20222,600,000 shares $46.80 million -10.0%11.4%4.8 $18.00 10/31/20222,890,000 shares $51.15 million +9.5%12.6%5.6 $17.70 10/15/20222,640,000 shares $37.75 million +6.0%11.5%6.2 $14.30 9/30/20222,490,000 shares $36.90 million +9.7%10.9%5.7 $14.82 9/15/20222,270,000 shares $37.18 million +1.3%9.9%4.9 $16.38 8/31/20222,240,000 shares $31.45 million -14.2%9.8%4.1 $14.04 8/15/20222,610,000 shares $56.56 million -7.8%11.4%4.4 $21.67 7/31/20222,830,000 shares $49.67 million -2.1%12.4%4.5 $17.55 7/15/20222,890,000 shares $48.41 million -2.7%12.7%4.4 $16.75 6/30/20222,970,000 shares $46.75 million -12.1%13.1%4 $15.74 6/15/20223,380,000 shares $44.99 million +1.2%14.9%4.6 $13.31 5/31/20223,340,000 shares $66.40 million +8.1%14.7%5 $19.88 5/15/20223,090,000 shares $52.47 million +1.3%13.6%4.8 $16.98 4/30/20223,050,000 shares $59.11 million +24.0%13.4%5.1 $19.38 4/15/20222,460,000 shares $65.21 million -5.0%10.8%4 $26.51 3/31/20222,590,000 shares $69.83 million +9.8%11.4%5 $26.96 3/15/20222,360,000 shares $43.80 million -4.5%10.4%4.4 $18.56 2/28/20222,470,000 shares $59.21 million -4.6%10.9%4.3 $23.97 2/15/20222,590,000 shares $64.36 million -1.9%11.4%4.4 $24.85 1/31/20222,640,000 shares $68.98 million +17.3%11.6%4.2 $26.13 1/15/20222,250,000 shares $75.33 million -4.3%9.9%3.7 $33.48 12/31/20212,350,000 shares $86.97 million +10.9%10.4%4.1 $37.01 12/15/20212,120,000 shares $75.30 million -15.2%9.3%3.6 $35.52 11/30/20212,500,000 shares $99.38 million +12.1%11.0%5 $39.75 11/15/20212,230,000 shares $79.23 million +9.9%9.8%4.6 $35.53 10/29/20212,030,000 shares $91.25 million +8.0%9.3%3.3 $44.95 10/15/20211,880,000 shares $85.65 million -2.6%8.7%2.2 $45.56 9/30/20211,930,000 shares $92.22 million -8.1%8.9%2.3 $47.78 9/15/20212,100,000 shares $109.81 million -14.6%9.7%2.4 $52.29 8/31/20212,460,000 shares $134.83 million +8.9%11.4%2.8 $54.81 8/13/20212,260,000 shares $108.53 million -38.6%10.5%2.6 $48.02 7/30/20213,680,000 shares $115.22 million -1.6%18.1%4.4 $31.31 7/15/20213,740,000 shares $104.79 million -6.5%17.3%7.2 $28.02 6/30/20214,000,000 shares $135.36 million -8.3%18.5%7.5 $33.84 6/15/20214,360,000 shares $146.15 million -13.0%20.2%8.1 $33.52 5/28/20215,010,000 shares $146.39 million -2.9%23.2%9.1 $29.22 5/14/20215,160,000 shares $133.08 million +13.4%N/A7.8 $25.79 4/30/20214,550,000 shares $169.58 million +12.1%N/A6.2 $37.27 4/15/20214,060,000 shares $162.08 million +7.7%N/A4.9 $39.92 3/31/20213,770,000 shares $146.09 million +18.9%N/A3.2 $38.75 3/15/20213,170,000 shares $156.85 million -0.6%N/A1.8 $49.48Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. 2/26/20213,190,000 shares $164.06 million +23.2%N/A1.7 $51.43 2/12/20212,590,000 shares $204.01 million -10.1%N/A1.4 $78.77 1/29/20212,880,000 shares $188.58 million -15.8%N/A1.5 $65.48 1/15/20213,420,000 shares $212.96 million +7.9%N/A1.8 $62.27 12/31/20203,170,000 shares $148.07 million -14.3%N/A1.9 $46.71 12/15/20203,700,000 shares $397.90 million -19.4%N/A3.7 $107.54 11/30/20204,590,000 shares $348.84 million -2.1%N/A5.1 $76.00 11/15/20204,690,000 shares $222.63 million +4.0%N/A6.5 $47.47 10/30/20204,510,000 shares $247.96 million +8.7%N/A6.6 $54.98 10/15/20204,150,000 shares $214.02 million +9.5%N/A6 $51.57 9/30/20203,790,000 shares $162.59 million +70.0%N/A5 $42.90 9/15/20202,230,000 shares $93.79 million +44.8%N/A2.7 $42.06 8/31/20201,540,000 shares $74.29 million -2.5%N/A1.9 $48.24 8/14/20201,580,000 shares $76.19 million -4.2%N/A1.8 $48.22 7/31/20201,650,000 shares $86.18 million +34.2%N/A1.9 $52.23 7/15/20201,230,000 shares $70.32 million -36.9%N/A1.3 $57.17 6/30/20201,950,000 shares $91.14 million +85.7%N/A2.3 $46.74 6/15/20201,050,000 shares $40.33 million +123.6%N/A1.5 $38.41 5/29/2020469,700 shares $18.29 million +5.4%N/A0.8 $38.94 5/15/2020445,700 shares $20.16 million +4.6%N/A0.8 $45.24 4/30/2020426,100 shares $14.70 million +27.2%N/A1 $34.50 4/15/2020335,000 shares $6.03 million +58.3%3.8%1.5 $18.00 3/31/2020211,600 shares $4.78 million +6.0%2.4%1.3 $22.57 3/13/2020199,600 shares $3.03 million +33.7%2.5%0.6 $15.19 2/28/2020149,300 shares $1.92 million -14.8%1.9%1.3 $12.87 2/14/2020175,200 shares $2.37 million +18.1%2.2%2.2 $13.54 1/31/2020148,400 shares $2.08 million -5.8%1.8%2 $13.99 1/15/2020157,500 shares $2.17 million -14.0%2.0%2.2 $13.80 12/31/2019183,100 shares $2.14 million +2.9%2.3%2.6 $11.67 ARCT Short Interest - Frequently Asked Questions What is Arcturus Therapeutics' current short interest? Short interest is the volume of Arcturus Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 4,370,000 shares of ARCT short. 17.78% of Arcturus Therapeutics' shares are currently sold short. Learn More on Arcturus Therapeutics' current short interest. What is a good short interest ratio for Arcturus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARCT shares currently have a short interest ratio of 11.0. Learn More on Arcturus Therapeutics's short interest ratio. Which institutional investors are shorting Arcturus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arcturus Therapeutics: Barclays PLC, Barclays PLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Arcturus Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.78% of Arcturus Therapeutics' floating shares are currently sold short. Is Arcturus Therapeutics' short interest increasing or decreasing? Arcturus Therapeutics saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 4,370,000 shares, a decrease of 2.5% from the previous total of 4,480,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Arcturus Therapeutics' float size? Arcturus Therapeutics currently has issued a total of 27,087,000 shares. Some of Arcturus Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Arcturus Therapeutics currently has a public float of 24,580,000 shares. How does Arcturus Therapeutics' short interest compare to its competitors? 17.78% of Arcturus Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arcturus Therapeutics: Galapagos NV (2.68%), Xencor, Inc. (6.37%), Evotec SE (0.14%), Arcutis Biotherapeutics, Inc. (20.10%), Nurix Therapeutics, Inc. (13.20%), Arcus Biosciences, Inc. (16.69%), Kiniksa Pharmaceuticals, Ltd. (5.57%), Immunocore Holdings plc (14.78%), Ocular Therapeutix, Inc. (6.78%), Mesoblast Limited (1.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Arcturus Therapeutics stock? Short selling ARCT is an investing strategy that aims to generate trading profit from Arcturus Therapeutics as its price is falling. ARCT shares are trading down $0.51 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcturus Therapeutics? A short squeeze for Arcturus Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ARCT, which in turn drives the price of the stock up even further. How often is Arcturus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARCT, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Galapagos Short Interest Xencor Short Interest Evotec Short Interest Arcutis Biotherapeutics Short Interest Nurix Therapeutics Short Interest Arcus Biosciences Short Interest Kiniksa Pharmaceuticals Short Interest Immunocore Short Interest Ocular Therapeutix Short Interest Mesoblast Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARCT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
